Subscribe to RSS
DOI: 10.1055/s-2007-968147
© Georg Thieme Verlag Stuttgart · New York
Eine offene Studie - Risperidon-Schmelztabletten in der Akutbehandlung exazerbierter schizophrener Patienten
An open-label observational study - Treatment of acutely exacerbated psychosis with risperidone fast orally disintegrating tabletsPublication History
Publication Date:
22 January 2007 (online)

Die Eignung atypischer Antipsychotika zur Initialbehandlung akuter Psychosen wird immer noch von vielen Klinikern in Zweifel gezogen. In einer wissenschaftlichen Studie wurde die Behandlung 191 schwerkranker Patienten mit einer akut exazerbierten Schizophrenie mit Risperidon Schmelztabletten dokumentiert. Fast 70 % aller Patienten waren nach 2 Stunden ausreichend beruhigt, innerhalb von 7 Tagen kam es zu einer signifikanten und klinisch relevanten Besserung von Positiv- und Negativsymptomen. Die Medikation wurde gut vertragen und die Einnahmesicherheit als sehr hoch eingestuft. Risperidon Schmelztabletten können aufgrund des raschen Wirkeintritts zur Akutbehandlung akuter Psychosen eingesetzt werden. Dadurch kann eine Umstellung der Medikation im weiteren Therapieverlauf entfallen.
Many clinicians still rely on conventional high-potency neuroleptics to treat acute psychosis, despite the broad use of atypical antipsychotics in subacute and chronic schizophrenia. In an open observational study the treatment of 191 acutely exacerbated schizophrenic patients, treated with risperidone fast orally disintegrating tablets, was documented. 70 % of all patients were calm within 2 hours after initiation of therapy. Within 7 days, positive and negative symptoms were significantly reduced. In general, the medication was well tolerated. The reliability of medication intake was considered to be high. Risperidone fast orally disintegrating tablets are an effective and safe treatment for severe acute psychosis. This avoids problems typically associated with the initial use of high-potency neuroleptics: patients have not to be switched to other medication for long-erm treatment. Also will less adverse events improve the compliance of schizophrenic patients.
Literatur
- 1 Naber D, Lambert M, Krausz M, Haasen C. Atypische Neuroleptika in der Behandlung schizophrener Patienten. Bremen: UNI-MED Verlag. 2000;
- 2 Möller HJ. Aktuelle Bewertung neuer/ atypischer Neuroleptika. Nervenarzt. 2000; 71 329-344
- 3 Levy RH. Sedation in acute and chronic agitation. Pharmacotherapy. 1996; 16 152S-159S
- 4 Hillard JR. Emergency treatment of acute psychosis. J Clin Psychiatry. 1998; 59 57-60
- 5 Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J. 2003; 20 339-346
- 6 Bundesinstitut für Arzneimittel und Medizinprodukte . Empfehlung zur Planung und Durchführung von Anwendungsbeobachtungen. Bundesanzeiger. 1998; 229 16884
- 7 Windeler J. Anwendungsbeobachtungen - Verharren in der „Schmuddelecke”. Deutsches Ärzteblatt. 2000; 42 2756-7
- 8 Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry. 1996; 57 68-71
- 9 Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol. 1995; 10 207-213
- 10 Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001; 62 153-157
- 11 Lejeune J, Larmo I, Chrzanowski W, Witte R, Karavatos A, Schreiner A, Lex A, Medori R. Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis. Int Clin Psychopharmacol. 2004; 19 259-69
- 12 Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in Schizophrenia. J Clin Psychopharmacol. 1995; 15 243-249
- 13 Pajonk FG, Schreiner A, Peters S, Retting K, Degner D, Rüther E. Initialtherapie mit Risperidon in der Akuttherapie schizophrener Patienten - eine Interimsanalyse. Fortschr Neurol Psychiat. 2003; 71 249-254
- 14 Hovens JE, Dries PJ, Melamn CT, Wapenaar RJ, Loonen AJ. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. J Psychopharmacol. 2005; 19 51-7
- 15 Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002; 59 441-8
- 16 Brook S, Luvcey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M Study Group. J Clin Psychiatry. 2000; 61 933-941
- 17 Kinon BJ, Hill AL, Liu H, Kollack-Walker S. Olanzapine orally disintegrating tabletzs in the treatment of acutely ill non-compliant patients with schizophrenia. In J Neuropsychopharmacol. 2003; 6 97-102
- 18 Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Doherty JP. The Expert Consensus Guideline Series. Treatment of behavioural emergencies. Postgrad Med. 2001; 1-88
Korrespondenzadresse:
Dr. Claus Normann
Abtl. Psychiatrie und Psychotherapie, Universitätsklinikum Freiburg
Hauptstr. 5
79104 Freiburg
Email: claus.normann@uniklinik-freiburg.de